A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
NCT07764237 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 375
Last updated 2026-08-13
Summary
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups
Conditions
- Respiratory Syncytial Virus (RSV)
- Human Metapneuomovirus (hMPV)
Interventions
- BIOLOGICAL
-
mRNA-1365 (Profile 2)
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1345 (Profile 1)
Sterile liquid for injection
- BIOLOGICAL
-
mRNA-1345 (Profile 3)
Sterile liquid for injection
Sponsors & Collaborators
-
ModernaTX, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-08-16
- Primary Completion
- 2027-07-20
- Completion
- 2027-07-20
- FDA Drug
- Yes
Countries
- Canada
- United Kingdom
Study Locations
More Related Trials
-
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
NCT05127434 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
NCT07628049 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
NCT07208461 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
NCT06097299 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
NCT07734649 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
NCT04528719 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
NCT03814590 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
NCT06573281 ·Status: COMPLETED ·Phase: PHASE1
-
Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
NCT06604767 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older
NCT07128121 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above
NCT06645665 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
NCT04798001 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
NCT06556147 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age
NCT05903183 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
NCT02298179 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults
NCT06287450 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
NCT04796896 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older
NCT06904222 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
NCT02873286 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older
NCT05327816 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
NCT04908683 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
NCT06143046 ·Status: COMPLETED ·Phase: PHASE2